Personalized eye drops aim to stretch time between injections for blinding disease
NCT ID NCT07461441
Summary
This study is testing a personalized treatment schedule for a drug called faricimab, which is injected into the eye. It aims to control a serious eye disease called polypoidal choroidal vasculopathy (PCV), which can cause vision loss. The main goal is to see if patients can safely go longer between injections—up to 16 weeks or more—while still keeping the disease under control and preserving their vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yeungnam university medical center
RECRUITINGDaegu, Namgu, 42415, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.